Literature DB >> 12455069

Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy.

M P Carrieri, C Pradier, P Piselli, M Piche, E Rosenthal, P Heudier, J Durant, Diego Serraino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12455069     DOI： 10.1002/ijc.10790

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  14 in total

1.  Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study.

Authors:  Eliane Rohner; Fabio Valeri; Mhairi Maskew; Hans Prozesky; Helena Rabie; Daniela Garone; Diana Dickinson; Cleophas Chimbetete; Priscilla Lumano-Mulenga; Izukanji Sikazwe; Natascha Wyss; Kerri M Clough-Gorr; Matthias Egger; Benjamin H Chi; Julia Bohlius
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

Review 2.  Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings.

Authors:  Aggrey S Semeere; Naftali Busakhala; Jeffrey N Martin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

Review 3.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.

Authors:  Meredith S Shiels; Stephen R Cole; Scott Wegner; Haroutune Armenian; Joan S Chmiel; Anuradha Ganesan; Vincent C Marconi; Otoniel Martinez-Maza; Jeremy Martinson; Amy Weintrob; Lisa P Jacobson; Nancy F Crum-Cianflone
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-01       Impact factor: 3.731

5.  Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era.

Authors:  Julia Bohlius; Fabio Valeri; Mhairi Maskew; Hans Prozesky; Daniela Garone; Mazvita Sengayi; Matthew P Fox; Mary-Ann Davies; Matthias Egger
Journal:  Int J Cancer       Date:  2014-05-02       Impact factor: 7.396

Review 6.  Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.

Authors:  Oluwatoyin F Gbabe; Charles I Okwundu; Martin Dedicoat; Esther E Freeman
Journal:  Cochrane Database Syst Rev       Date:  2014-08-13

7.  CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.

Authors:  Mark Bower; Martin Fisher; Teresa Hill; Iain Reeves; John Walsh; Chloe Orkin; Andrew N Phillips; Loveleen Bansi; Richard Gilson; Philippa Easterbrook; Margaret Johnson; Brian Gazzard; Clifford Leen; Deenan Pillay; Achim Schwenk; Jane Anderson; Kholoud Porter; Mark Gompels; Caroline A Sabin
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

8.  Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.

Authors:  Mary Cianfrocca; Sandra Lee; Jamie Von Roenn; Anil Tulpule; Bruce J Dezube; David M Aboulafia; Richard F Ambinder; Jeannette Y Lee; Susan E Krown; Joseph A Sparano
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

9.  Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition.

Authors:  Yasunori Ota; Tsunekazu Hishima; Makoto Mochizuki; Yoshinori Kodama; Suzuko Moritani; Naoki Oyaizu; Sohtaro Mine; Atsushi Ajisawa; Junko Tanuma; Tomoko Uehira; Shotaro Hagiwara; Keishiro Yajima; Yusuke Koizumi; Takuma Shirasaka; Yuki Kojima; Hirokazu Nagai; Yoshiyuki Yokomaku; Yumiko Shiozawa; Tomohiko Koibuchi; Aikichi Iwamoto; Shinichi Oka; Hideki Hasegawa; Seiji Okada; Harutaka Katano
Journal:  Cancer Med       Date:  2014-01-10       Impact factor: 4.452

10.  The interaction between smoking status and highly active antiretroviral therapy (HAART) use on the risk of Kaposi's sarcoma (KS) in a cohort of HIV-infected men.

Authors:  H N Luu; E S Amirian; M E Scheurer
Journal:  Br J Cancer       Date:  2013-02-19       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.